Anna Portyanko

ORCID: 0000-0003-2399-117X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Microtubule and mitosis dynamics
  • Thyroid Cancer Diagnosis and Treatment
  • Immune cells in cancer
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Nutrition, Genetics, and Disease
  • CAR-T cell therapy research
  • Cancer Genomics and Diagnostics
  • Immunotherapy and Immune Responses
  • Colorectal Cancer Screening and Detection
  • Ovarian cancer diagnosis and treatment
  • BRCA gene mutations in cancer
  • Viral Infectious Diseases and Gene Expression in Insects
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Surgical Treatments
  • Barrier Structure and Function Studies
  • DNA Repair Mechanisms
  • Cancer Treatment and Pharmacology
  • Digestive system and related health
  • Celiac Disease Research and Management
  • Radiomics and Machine Learning in Medical Imaging
  • Pancreatic and Hepatic Oncology Research
  • Ubiquitin and proteasome pathways
  • Inflammatory Biomarkers in Disease Prognosis
  • Endometrial and Cervical Cancer Treatments

N.N. Alexandrov National Cancer Centre
2017-2025

Belarusian State Medical University
2002-2022

National Research Center for Hematology Russian Academy of Medical Sciences
2002

Institute of Biophysics and Cell Engineering
2002

Belarusian Research Center For Pediatric Oncology and Hematology
2002

Belarusian State University
2002

Cancer immunity is based on the interaction of a multitude cells in spatial context tumour tissue. Clinically relevant immune signatures are therefore anticipated to fundamentally improve accuracy predicting disease progression.Through multiplex situ analysis we evaluated 15 cell classes 1481 samples. Single-cell and bulk RNAseq data sets were used for functional validation prognostic predictive associations.By combining information anti-tumoural CD8+ lymphocytes supportive CD68+CD163+...

10.1016/j.ebiom.2023.104452 article EN cc-by EBioMedicine 2023-01-30

Aim : to characterize CD155 expression in primary choroidal melanoma cells and determine its prognostic value for survival. Material methods 68 patients with were included. The levels patterns of tumor tissues studied using immunohistochemical method. Regression analysis was performed identify independent factors predicting the course disease. Results 51 % cases, membrane registered cells. In group tumors any type CD155, signs poor prognosis statistically significantly more common. Membrane...

10.18027/2224-5057-2024-029 article EN cc-by Malignant tumours 2025-01-23

// Artur Mezheyeuski 1, 2 , Maja Bradic Lindh * Tormod Kyrre Guren 3, 4, Anca Dragomir 5 Per Pfeiffer 6 Elin H. Kure 7 Tone Ikdahl 8 Eva Skovlund 9 Sara Corvigno 1 Carina Strell Kristian Pietras 10 Fredrik Ponten Jan Mulder 11 Camilla Qvortrup Anna Portyanko Kjell Magne Tveit 3 Bengt Glimelius 5, # Halfdan Sorbye 12, Arne Östman Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden Pathology, Belarusian State Medical University, Minsk, Belarus Oncology, Oslo University...

10.18632/oncotarget.9632 article EN Oncotarget 2016-05-26

Tubulin is a heterodimer of α and β subunits, both existing as isotypes differing in amino acid sequence encoded by different genes. Specific tubulin have associations with cancer that are not well understood. Previous studies found βII-tubulin expressed number transformed cells this isotype cell nuclei non-microtubule form. The association βII expression its nuclear localization progression has previously been addressed. We here used monoclonal antibody to examine patients colorectal whose...

10.3390/cells8010025 article EN cc-by Cells 2019-01-07

Abstract The complexity of tumor histomorphology reflects underlying biology impacting on natural course and response to treatment. This study presents a method computer-aided analysis tissue sections, relying multifractal (MF) analyses, cytokeratin-stained sections which quantitatively evaluates the morphological tumor-stroma interface. approach was applied colon cancer collection, from an adjuvant treatment randomized study. Metrics obtained with acted as independent markers for disease,...

10.1038/srep36149 article EN cc-by Scientific Reports 2016-11-02

Claudin-2 is a trans-membrane protein-component of tight junctions in epithelial cells. Elevated claudin-2 expression has been reported colorectal cancer (CRC). The aim this study was to investigate the patterns human CRC samples and analyze its association with clinical characteristics treatment outcome. TMAs primary tumors from two cohorts metastatic (mCRC) were used. IHC staining evaluated semi-quantitative manner different regions cell types. also analyzed by immunofluorescence cultures...

10.1007/s00428-017-2263-3 article EN cc-by Virchows Archiv 2017-11-13

Vascular characteristics, hypoxia and tumor budding are features that have been implied in the biology prognosis of colorectal cancer. Internal relationships inter- intra-tumoral variation these properties remain to be determined. In current study we characterized blood vessel status different areas CRC peritumoral fibroblastic stroma. Analyses characteristics supplemented by characterization hypoxia. revealed significantly lower values perimeter (VP) lumen area (VL) at invasive front...

10.14670/hh-11-613 article EN PubMed 2015-10-01

Identification of biomarkers associated with benefit adjuvant chemotherapy in stage II/III colon cancer is an important task. Vessel density (VD) and tumour stroma were analysed a randomised-trial-derived discovery cohort (n = 312) group population-based validation 85). VD was scored separately the centre, invasive margin peritumoral compartments quantitated as VD/total tissue area or VD/stroma area. High stroma-normalised significantly longer time to recurrence overall survival (OS) (p...

10.1038/s41416-019-0519-1 article EN cc-by British Journal of Cancer 2019-07-09

Elevated βIII-tubulin levels are associated with resistance to a broad spectrum of drugs in different carcinomas and poor prognosis various epithelial cancers. 5-Fluorouracil (5-FU) is widely used standard drug chemotherapeutic regimens for colorectal cancer treatment, although the 5-FU major obstacle successful therapy.The aim study was compare invasive adhesion properties expression 5-fluorouracil (5-FU)-resistant (CRC) cell line HCT116 parental cells.The 5-FU-resistant established by...

10.32471/exp-oncology.2312-8852.vol-43-no-2.16314 article EN cc-by-nc Experimental Oncology 2021-06-30

Introduction. The search for new antitumor agents among plants of local flora is one the options expanding existing list chemotherapeutic drugs. A promising source such may be an invasive and weedy species territory Republic Belarus Russian Federation – Heracleum Sosnowskyi . This contains coumarins, which properties have been established, so can considered a raw material these biologically active substances. Aim. To analyze cytostatic effect extracts from herb, inflorescences roots on tumor...

10.33380/2305-2066-2025-14-1-1978 article EN cc-by Drug development & registration 2024-12-27

Approximately 20% of adult patients with Burkitt's lymphoma (BL) have relapsed/refractory disease, which is characterized by poor overall survival (OS) and virtually no therapeutic options after failure two lines chemotherapy, due in part to the peculiarities tumor cell biology. Improved treatment strategies are an unmet need for these patients. There been individual attempts use chimeric antigen receptor (CAR)-T therapy this patient population using anti-CD19, CD20, CD22 cells. In our...

10.33696/immunology.6.204 article EN Journal of Cellular Immunology 2024-01-01

Gluten-dependency of clinical manifestations, serological and histological abnormalities is the key feature celiac disease (CD) [1].That means, that in most CD patients, all symptoms as well mucosal atrophy are potentially reversible after gluten exclusion based on this fact, gluten-free diet (GFD) main treatment option.Classical conception could be described presence symptoms, CDmarkers intestinal mucosa which resolve GFD reappear renewal intake or continue to exist patients a...

10.12691/ijcd-2-1-9 article EN International Journal of Celiac Disease 2016-05-05

The N.N. Alexandrov National Cancer Center of Belarus organized a collaborative international conference entitled 'Current Concepts and Controversies in Gynecologic Urologic Oncology' with the International Society United States Institute. International, regional, national experts presented recent developments local conditions treatment gynecologic cancers. Findings were reviewed intent optimizing management women cancers across Commonwealth Independent region. At end conference, resolution...

10.1097/igc.0000000000001126 article EN cc-by-nc-nd International Journal of Gynecological Cancer 2017-10-17

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)

10.1530/endoabs.73.aep668 article EN Endocrine Abstracts 2021-05-15

Abstract Background : Studies in experimental models have implied perivascular cells (PC) as regulators of multiple aspects tumor biology, including growth, metastasis, immune cell activity and response to treatment. However, the extent inter- intra-case variability clinical samples, potential biomarkers, remain poorly characterized. Methods: We developed an integrated analytical pipeline investigate vascular PC status samples. The procedure uses double-staining with one endothelial marker...

10.1158/1538-7445.tme16-c38 article EN Cancer Research 2016-07-28

e14525 Background: Tumor progression and metastasis are regulated by the tumor stroma (TS), suggesting a largely unexplored prognostic significance of its features. The aim this study was to perform multi-parametric analysis colorectal cancer (CRC) explore digitally quantified TS characteristics Methods: A tissue microarray with 247 primary stage IV CRC tumors from phase III NORDIC-VII used. Tumors samples were subjected four double-stainings (CD34 either ASMA, PDGFbR, Desmin or Ki67)....

10.1200/jco.2014.32.15_suppl.e14525 article EN Journal of Clinical Oncology 2014-05-20
Coming Soon ...